BBOT (BridgeBio Oncology Therapeutics) 3-Month Share Buyback Ratio: -0.03% (As of Jun. 2026 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BBOT BridgeBio Oncology Therapeutics Inc BBOT
12 GF Score
Price $8.74
View Full Analysis

What is BridgeBio Oncology Therapeutics 3-Month Share Buyback Ratio?

BridgeBio Oncology Therapeutics BBOT -4.69% 12 3-Month Share Buyback Ratio is -0.03 as of Jun. 2026. GuruFocus rates BBOT with a GF Score™ of 12/100.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. BridgeBio Oncology Therapeutics's current 3-Month Share Buyback Ratio was -0.03%.

BridgeBio Oncology Therapeutics  (NAS:BBOT) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

BridgeBio Oncology Therapeutics 3-Month Share Buyback Ratio Related Terms

BBOT vs CTMX, OMER, STTK: 3-Month Share Buyback Ratio Comparison

For the Biotechnology subindustry, BridgeBio Oncology Therapeutics's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BridgeBio Oncology Therapeutics 3-Month Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Oncology Therapeutics's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where BridgeBio Oncology Therapeutics's 3-Month Share Buyback Ratio falls into.


BBOT
12GF Score
BridgeBio Oncology Therapeutics Inc BBOT
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BridgeBio Oncology Therapeutics 3-Month Share Buyback Ratio Calculation

BridgeBio Oncology Therapeutics's 3-Month Share Buyback Ratio for the quarter that ended in Jun. 2026 is calculated as

3-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Mar. 2026 ) - Shares Outstanding (EOP) (Jun. 2026 )) / Shares Outstanding (EOP) (Mar. 2026 )
=(80.089 - 80.115) / 80.089
=-0.03%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 3-Month Share Buyback Ratio of -0.03 mean?
BridgeBio Oncology Therapeutics (BBOT) has a 3-Month Share Buyback Ratio of -0.03 as of Jun. 2026. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for BridgeBio Oncology Therapeutics and its competitors.
Is BridgeBio Oncology Therapeutics' 3-Month Share Buyback Ratio too high?
BridgeBio Oncology Therapeutics' current 3-Month Share Buyback Ratio is -0.03. Overall, BridgeBio Oncology Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Oncology Therapeutics' 3-Month Share Buyback Ratio compare to CTMX and OMER?
BridgeBio Oncology Therapeutics' 3-Month Share Buyback Ratio of -0.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Biotechnology company?
A good 3-Month Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for BridgeBio Oncology Therapeutics and its competitors. BridgeBio Oncology Therapeutics's current 3-Month Share Buyback Ratio is -0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Oncology Therapeutics stock overvalued right now?
BridgeBio Oncology Therapeutics (BBOT) has a current 3-Month Share Buyback Ratio of -0.03. The current 3-Month Share Buyback Ratio is -0.03. BridgeBio Oncology Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For BridgeBio Oncology Therapeutics (BBOT), the current 3-Month Share Buyback Ratio is -0.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BridgeBio Oncology Therapeutics Business Description

Address 256 East Grand Avenue, Suite 104, South San Francisco, CA, USA, 94080
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
12GF Score

Get the complete analysis for BBOT

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.74
Price